



**THE FOUNDATION  
FOR SECURE  
MARKETS®**

#53795

**Date:** December 18, 2023

**Subject:** Neoleukin Therapeutics, Inc. - Reverse Split and Name/Symbol/CUSIP Change  
Option Symbol: NLTX  
New Symbol: NGNE2  
Date: 12/19/2023

Neoleukin Therapeutics, Inc. (NLTX) has announced a 1-for-4 reverse stock split and a name, symbol, CUSIP change. As a result of the reverse stock split and underlying changes, each NLTX Common Share will be converted into the right to receive 0.25 (New) Neurogene, Inc. (NGNE) Common Shares. The reverse stock split and underlying changes will become effective before the market open on December 19, 2023.

Additionally, under a CVR agreement, NLTX shareholders of record immediately prior to the effective time of the merger will receive one non-transferable Contingent Value Right (CVR) per share. The CVR represents a non-transferable contractual right to receive payments upon the occurrence of certain events as described in the 8-K SEC Filing dated November 30, 2023.

**NLTX options will not be adjusted to call for the delivery of the CVRs.**

**Contract Adjustment**

**Effective Date:** December 19, 2023

**Option Symbol:** NLTX changes to NGNE2

**Contract  
Multiplier:** 1

**Strike Divisor:** 1

**New Multiplier:** 100 (e.g., for premium or strike dollar extensions 1.00 will equal \$100)

**New Deliverable  
Per Contract:** 25 (New) Neurogene, Inc. (NGNE) Common Shares

**CUSIP:** NGNE (New): 64135M105

## **Pricing**

The underlying price for NGNE2 will be determined as follows:

$$\text{NGNE2} = 0.25 (\text{NGNE})$$

## **Disclaimer**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at [options@theocc.com](mailto:options@theocc.com). Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).